Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Preconditioning of swine heart with monophosphoryl lipid A improves myocardial preservation
Autore:
Yoshida, T; Engelman, RM; Engelman, DT; Rousou, JA; Maulik, N; Sato, M; Elliott, GT; Das, DK;
Indirizzi:
Baystate Med Ctr, Dept Surg, Div Cardiac Surg, Springfield, MA 01199 USA Baystate Med Ctr Springfield MA USA 01199 Surg, Springfield, MA 01199 USA Univ Connecticut, Sch Med, Dept Surg, Farmington, CT 06032 USA Univ Connecticut Farmington CT USA 06032 t Surg, Farmington, CT 06032 USA RIBI Immunochem Res Inc, Hamilton, MT 59840 USA RIBI Immunochem Res Inc Hamilton MT USA 59840 Inc, Hamilton, MT 59840 USA
Titolo Testata:
ANNALS OF THORACIC SURGERY
fascicolo: 3, volume: 70, anno: 2000,
pagine: 895 - 900
SICI:
0003-4975(200009)70:3<895:POSHWM>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
NITRIC-OXIDE; ADENOSINE RECEPTORS; RAT HEARTS; ISCHEMIA; REPERFUSION; ADAPTATION; PROTECTION; INJURY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Engelman, RM Baystate Med Ctr, Dept Surg, Div Cardiac Surg, 759 Chestnut St,Suite 4628,Springfield, MA 01199 USA Baystate Med Ctr 759 Chestnut St,Suite 4628 Springfield MA USA 01199
Citazione:
T. Yoshida et al., "Preconditioning of swine heart with monophosphoryl lipid A improves myocardial preservation", ANN THORAC, 70(3), 2000, pp. 895-900

Abstract

Background. Ischemic preconditioning has been proven to be a powerful toolfor myocardial protection in the setting of ischemia and reperfusion. A new drug to provide pharmacologic preconditioning, monophosphoryl lipid A (MLA), was administered 24 hours before an acute coronary occlusion in pigs todetermine the effect on pharmacologic preconditioning. Methods. Two studies were completed. In the first, swine were distributed into five groups: group I, control; group II,. aminoguanidine (AMG) (30 mg/kg), a selective inducible nitric oxide synthase (iNOS) blocker; group III,MLA (10 mu g/kg); group IV, MLA (35 mu g/kg); and group V, MLA and AMG (35mu g/kg and 30 mg/kg, respectively). Twenty-four hours after administration of the MLA, AMG, or both, regional left anterior descending coronary artery ischemia was induced for 15 minutes followed by one hour of global normothermic cardioplegic arrest and three hour reperfusion. Left ventricular function, tissue injury, and percentage of myocardial infarction were measured. Left ventricular myocardium in the left anterior descending coronary artery region was sampled for iNOS messenger RNA (mRNA) during ischemia and reperfusion. In the second study, pigs were sacrificed 0, 4, 6, 8, and 24 hrsafter MLA/AMG administration for iNOS mRNA determination in nonischemic myocardium. Results. Use of MLA significantly improved postischemic ventricular function, and reduced creatinine kinase release and percentage of infarction. Monophosphoryl lipid A induced expression of iNOS mRNA in nonischemic myocardium within four hours of administration which returned to base line by 24 hours. Normothermic regional ischemia then induced expression of iNOS mRNA, which returned to base line during reperfusion. Aminoguanidine completely abolished both MLA-induced and ischemia-induced iNOS mRNA and blocked the beneficial effects of MLA. Conclusions. Use of MLA can provide myocardial preservation through enhanced expression of iNOS mRNA. (Ann Thorac Surg 2000;70:895-900) (C) 2000 by The Society of Thoracic Surgeons.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 22:27:57